- Home
- SVT vs INAB Comparison
SVT vs INAB Comparison
Compare SVT & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVT
- INAB
- Stock Information
- Founded
- SVT 1959
- INAB 2016
- Country
- SVT United States
- INAB United States
- Employees
- SVT N/A
- INAB N/A
- Industry
- SVT Industrial Machinery/Components
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- SVT Consumer Discretionary
- INAB Health Care
- Exchange
- SVT Nasdaq
- INAB Nasdaq
- Market Cap
- SVT 31.3M
- INAB 14.2M
- IPO Year
- SVT N/A
- INAB 2021
- Fundamental
- Price
- SVT $11.74
- INAB $0.31
- Analyst Decision
- SVT
- INAB Strong Buy
- Analyst Count
- SVT 0
- INAB 3
- Target Price
- SVT N/A
- INAB $10.00
- AVG Volume (30 Days)
- SVT 8.9K
- INAB 383.7K
- Earning Date
- SVT 11-07-2024
- INAB 11-07-2024
- Dividend Yield
- SVT N/A
- INAB N/A
- EPS Growth
- SVT N/A
- INAB N/A
- EPS
- SVT 0.17
- INAB N/A
- Revenue
- SVT $46,639,000.00
- INAB N/A
- Revenue This Year
- SVT N/A
- INAB N/A
- Revenue Next Year
- SVT N/A
- INAB N/A
- P/E Ratio
- SVT $39.25
- INAB N/A
- Revenue Growth
- SVT 26.13
- INAB N/A
- 52 Week Low
- SVT $8.80
- INAB $0.28
- 52 Week High
- SVT $14.10
- INAB $2.48
- Technical
- Relative Strength Index (RSI)
- SVT 46.28
- INAB 23.66
- Support Level
- SVT $11.20
- INAB $0.28
- Resistance Level
- SVT $13.01
- INAB $0.33
- Average True Range (ATR)
- SVT 0.53
- INAB 0.04
- MACD
- SVT -0.12
- INAB -0.00
- Stochastic Oscillator
- SVT 12.15
- INAB 11.28
About SVT Servotronics Inc.
Servotronics Inc is a U.S based company that designs, manufactures, and markets servo valves, including torque motor, hydraulic, and pneumatic valves. The company has single reportable segment which is aerospace Its products are marketed and sold throughout the United States and in select foreign markets. These products are sold to commercial aviation manufacturers, government prime contractors, government subcontractors, and end-users.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.